Y-27632 Dihydrochloride: Selective ROCK1/2 Inhibitor for Cytoskeletal and Stem Cell Research

Executive Summary: Y-27632 dihydrochloride is a cell-permeable small molecule inhibitor that displays high selectivity for Rho-associated protein kinases ROCK1 (IC₅₀ ≈ 140 nM) and ROCK2 (K_i ≈ 300 nM), with >200-fold selectivity over PKC, PKA, MLCK, and PAK (APExBIO, product page). It disrupts Rho-mediated stress fiber formation, modulates G1/S cell cycle progression, and inhibits cytokinesis, making it a critical tool in cytoskeletal, stem cell, and cancer research (Hua et al., 2022, doi.org/10.1016/j.scr.2022.102832). Reliable solubility is achieved at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water, with storage at ≤4°C desiccated as solid. In vitro and in vivo studies show Y-27632 reduces smooth muscle proliferation and suppresses tumor invasion (APExBIO, A3008 kit). This article provides atomic, verifiable facts and workflow integration for researchers seeking robust, reproducible results.

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases central to actin cytoskeleton regulation, cell contractility, and motility (Hua et al., 2022). Rho/ROCK signaling is implicated in cell proliferation, apoptosis, migration, and differentiation. Aberrant ROCK activity contributes to pathological conditions including fibrosis, neurodegeneration, and cancer invasion. In stem cell biology, ROCK inhibition prevents dissociation-induced apoptosis, enhancing cell viability and cloning efficiency. Y-27632 dihydrochloride, by selectively inhibiting ROCK1/2, enables precise dissection of Rho/ROCK-mediated processes, supporting translational studies in tissue engineering, disease modeling, and oncology (see also). Unlike pan-kinase inhibitors, Y-27632's high selectivity minimizes off-target effects, providing cleaner mechanistic insights.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride competitively binds to the ATP-binding pocket of the catalytic domains of ROCK1 and ROCK2 (APExBIO). This binding inhibits kinase activity, blocking downstream phosphorylation of targets such as myosin light chain (MLC) and LIM kinase. The result is reduced actomyosin contractility, loss of stress fibers, and impaired focal adhesion formation. In stem cell cultures, this prevents apoptosis triggered by single-cell dissociation. In tumor cells, Y-27632 suppresses motility and invasion by destabilizing the actin cytoskeleton. Quantitative inhibition constants are: IC₅₀ ≈ 140 nM (ROCK1), K_i ≈ 300 nM (ROCK2), and >200-fold selectivity over PKC, PKA, MLCK, and PAK (APExBIO). The compound does not significantly inhibit unrelated kinases at concentrations up to 50 μM.

Evidence & Benchmarks

• Y-27632 dihydrochloride enhances viability and cloning efficiency of human induced pluripotent stem cells (iPSCs) by >70% when used at 10 μM during single-cell passaging (Hua et al., Fig. 1, doi.org/10.1016/j.scr.2022.102832).
• Selective inhibition of ROCK1 with IC₅₀ ≈ 140 nM and ROCK2 with K_i ≈ 300 nM confirmed via in vitro kinase assays (APExBIO).
• Over 200-fold selectivity for ROCK1/2 compared to PKC, PKA, MLCK, and PAK at 10 μM, minimizing off-target effects (APExBIO).
• Reduces proliferation of prostatic smooth muscle cells in vitro in a concentration-dependent manner (APExBIO datasheet, A3008).
• Suppresses tumor invasion and metastasis in mouse models at 10–30 mg/kg dosed intraperitoneally, reducing pathological tumor structures (APExBIO, A3008).
• All iPSC lines generated with Y-27632 supplementation retain pluripotency, verified by expression of Oct4, Nanog, TRA-1-60, and SSEA4, and demonstrate trilineage differentiation in teratoma assays (Hua et al., Table 1, doi.org/10.1016/j.scr.2022.102832).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is a reference compound for modulating the Rho/ROCK signaling pathway in diverse systems.

• Stem Cell Viability: Protects iPSCs and human ESCs from apoptosis during dissociation and passaging.
• Cytoskeletal Research: Disrupts stress fiber formation and cell contractility, enabling studies of migration and mechanotransduction.
• Tumor Biology: Inhibits invasion, migration, and metastasis in cancer models.
• Neuroscience: Facilitates survival of primary neurons and neural precursor cells in vitro.
• Organoid Systems: Enhances growth and reproducibility in 3D organoid cultures (further mechanistic discussion).

This article extends prior analyses (see here) by consolidating specific quantitative benchmarks and practical preparation details for Y-27632. It also clarifies distinctions in selectivity and off-target profiles compared to broader kinase inhibitors (see our application note).

Common Pitfalls or Misconceptions

• Not a pan-kinase inhibitor: Y-27632 dihydrochloride is selective for ROCK1/2 and does not meaningfully inhibit PKC, PKA, MLCK, or PAK at standard concentrations (APExBIO).
• Not cytotoxic at standard doses: No evidence of general cytotoxicity at ≤10 μM for stem cells or ≤50 μM for most cell lines (Hua et al., 2022).
• Does not induce pluripotency: Y-27632 supports viability but does not by itself reprogram somatic cells (see methods).
• Not recommended for long-term solution storage: Prepare fresh solutions or store aliquots at -20°C; avoid repeated freeze-thaw cycles (APExBIO).
• Solubility varies by solvent: DMSO allows highest concentration; warming or sonication may be required for complete dissolution (APExBIO).

Workflow Integration & Parameters

Y-27632 dihydrochloride (A3008) from APExBIO is supplied as a solid and should be stored desiccated at 4°C or below. For preparation, dissolve at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water. Use mild warming (37°C) or sonication if necessary. Stock solutions may be stored at -20°C for several months, avoiding repeated freeze-thaw cycles.

For stem cell passaging, 10 μM Y-27632 is typically added to culture medium 1–24 hours post-dissociation. For cytoskeletal studies, titrate between 1–50 μM depending on cell type and endpoint. For in vivo tumor models, dosing regimens of 10–30 mg/kg i.p. are standard in mice (APExBIO). Always reference the latest peer-reviewed protocols and adjust for experimental context.

For further guidance on integrating Y-27632 in complex disease modeling or regenerative protocols, see our in-depth mechanistic discussion here—this article updates practical parameters and clarifies selectivity benchmarks.

Conclusion & Outlook

Y-27632 dihydrochloride is the gold standard for selective, potent ROCK inhibition in cell biology, stem cell research, and cancer models. Its high selectivity, robust solubility, and well-validated mechanistic profile underpin its widespread adoption. APExBIO's A3008 kit ensures quality and batch consistency for reproducible workflows. As Rho/ROCK pathway modulation continues to inform next-generation disease modeling and therapeutic development, Y-27632 remains indispensable for precision experimental design. Researchers are advised to reference peer-reviewed protocols and product documentation for optimal results (product page).